rofecoxib has been researched along with Huntington Disease in 3 studies
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Malonic acid (MA) is a reversible inhibitor of succinate dehydrogenase (SDH) which induces mitochondrial dysfunction followed by secondary excitotoxicity and apoptosis due to generation of reactive oxygen species." | 1.39 | Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats. ( Kalonia, H; Kumar, A; Mishra, J; Sharma, N, 2013) |
| "Quinolinic acid (QA) is a well-known excitotoxic agent that could induce behavioral, morphological and biochemical alterations similar with symptoms of Huntington's disease (HD), by stimulating NMDA receptors." | 1.35 | Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status. ( Kalonia, H; Kumar, A; Kumar, P; Nehru, B, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, A | 2 |
| Sharma, N | 1 |
| Mishra, J | 1 |
| Kalonia, H | 2 |
| Kumar, P | 1 |
| Nehru, B | 1 |
| Norflus, F | 1 |
| Nanje, A | 1 |
| Gutekunst, CA | 1 |
| Shi, G | 1 |
| Cohen, J | 1 |
| Bejarano, M | 1 |
| Fox, J | 1 |
| Ferrante, RJ | 1 |
| Hersch, SM | 1 |
3 other studies available for rofecoxib and Huntington Disease
| Article | Year |
|---|---|
Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cy | 2013 |
Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status.
Topics: Animals; Body Weight; Caffeic Acids; Corpus Striatum; Cyclooxygenase 2 Inhibitors; Disease Models, A | 2009 |
Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice.
Topics: Acoustic Stimulation; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; As | 2004 |